Injectable Hydroxyapatite-Reinforced Methacrylated Recombinant Type III Collagen Microgels for Soft-Tissue Filling
Abstract
Injectable fillers that combine immediate volume restoration with a sustained biological response remain of considerable interest in minimally invasive aesthetic medicine. In this study, a hydroxyapatite-loaded methacrylated recombinant type III collagen microgel (HAp@rhCol III-MA) was prepared by in situ coprecipitation and photocrosslinking. Recombinant type III collagen (rhCol III) was functionalized with methacryloyl groups to obtain rhCol III-MA, after which a calcium phosphate phase was mineralized in the presence of the modified collagen and the collagen phase was crosslinked under ultraviolet irradiation. More than 80% of the microgel particles prepared at 900 rpm were 20-80 μm in diameter. Spectroscopic, elemental, thermal, and diffraction analyses supported the incorporation of a poorly crystalline, HAp-compatible calcium phosphate phase, while rheological measurements showed higher storage and loss moduli than those of rhCol III-MA gel. HAp@rhCol III-MA did not reduce NIH-3T3 cell viability at the tested concentrations and enhanced HUVEC scratch closure and tube-network formation in vitro. Following subcutaneous implantation in rats, the microgel retained more volume than rhCol III-MA during the early and intermediate observation periods, with residual volumes of 56.58 ± 3.03 mm3 for HAp@rhCol III-MA and 52.80 ± 1.79 mm3 for rhCol III-MA at day 59; the commercial type I collagen comparator retained 123.23 ± 2.80 mm3. The composite caused no evident tissue injury…
Read the paper
Related studies
- The Matrisome: In Silico Definition and In Vivo Characterization by Proteomics of Normal and Tumor Extracellular Matrices
- The Escherichia coli MG1655 in silico metabolic genotype: Its definition, characteristics, and capabilities
- In silico pharmacology for drug discovery: methods for virtual ligand screening and profiling
- In silico prediction of splice-altering single nucleotide variants in the human genome
- In silico clinical trials: how computer simulation will transform the biomedical industry
- In silico optimization of a guava antimicrobial peptide enables combinatorial exploration for peptide design
Go deeper in Evidence Hub
Evidence Hub adds a study data sheet (design, sample size, evidence level, key numbers), an AI summary and a chat grounded in the paper's text.